Conversely, at nontoxic concentrations, HDAC inhibitors can be used for the treatment of many debilitating conditions in the lungs such as COPD, inflammation, and COVID-19 infection (Shakespear et al., 2011). This evidence concerns the gene HDAC9 and chronic obstructive pulmonary disease.